A Phase 1/2 interventional study of Dextrose solution and Saline in Chronic Subdural Hematoma and Recurrent, sponsored by Carilion Clinic. Recruiting at 1 site in United States. Open to participants aged 18 Years to 100 Years. Per ClinicalTrials.gov, last updated 2026-11-16.
Sponsored by Carilion Clinic · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 22 studies in Hematoma, Subdural, Chronic with a site in United States — 10 open to participants now, 10 under way, none of them phase 3. Hematoma, Subdural, Chronic · United States.
Among the 22 studies in Hematoma, Subdural, Chronic with a site in United States, this one is the 6th largest by planned enrollment of the 15 interventional ones that give a count, is one of 3 that started in 2024, is the only one in phase 1/2, and was the 22nd registered.
113 studies on the registry are indexed under Hematoma, Subdural, Chronic; 50 are open to participants now.
Browse Hematoma, Subdural, Chronic studies →10 of the 22 studies in Hematoma, Subdural, Chronic with a site in United States are open now. Recruiting first, the newest first:
Arsenal Medical, Inc. · Sites in United States
Ages 18–90
Icahn School of Medicine at Mount Sinai · Sites in United States
Ages 18+
Ohio State University · Sites in United States
Ages 18+
Lahey Clinic · Sites in United States
Ages 18+
The University of Texas Medical Branch, Galveston · Sites in United States
Ages 40–90
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 36 Hematoma, Subdural, Chronic studies recruiting now, 26 (72%) set no upper age limit and 1 (3%) stops at 75 or younger; 1 takes children under 18; 1 takes healthy volunteers.
This study: 18 Years to 100 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
22 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 2 · Phase 3 1
First in 2014; this study’s year is marked. 3 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 68 is below the median of 180 across 87 interventional studies indexed under Hematoma, Subdural, Chronic.
Median enrollment 40 across the 15 interventional studies, 100 across the 7 observational. Of the 7 that completed or were terminated, 3 (43%) have results posted.
This tab as a report to print or save as PDF → With an account.
4 of 22 have an industry lead sponsor. The 10 most frequent:
Carilion Clinic is the lead sponsor of 76 studies on the registry; 16 are open to participants now.
Of its 9 completed or terminated interventional studies of FDA-regulated products, 2 (22%) have results posted.
Carilion Clinic has 2 studies filed under Hematoma, Subdural, Chronic — fewer than ten, so there is no comparison to draw.
3 of the studies in Hematoma, Subdural, Chronic with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07214623Kaneka Medical America LLCProspective Multi-center Single Arm Study for Subjects With Chronic Subdural Hematoma Treated With i-ED COILs, Either Alone or in Combination With Burr-holes or Mini-craniotomy | 2026-11-30 |
| NCT06181994Montefiore Medical CenterMiddle Meningeal Artery Embolization (MMAE) Outcomes for Chronic Subdural Hematoma (cSDH) | 2026-12 |
| NCT07715656Lahey ClinicAssessing Outcomes of Coil Embolization for Unilateral vs Bilateral Chronic Subdural Hematomas | 2027-04-30 |
Add all 3 to your calendar (.ics) → With an account.
Among the 22 studies in Hematoma, Subdural, Chronic with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
How can investigators improve recurrence rates of chronic subdural hematomas to reduce need for surgical intervention? Study investigators hypothesize that Dextrose 5% in 0.225% Sodium Chloride (D5 ¼NS) will increase the intracellular brain volume and water content post-operatively, reducing the residual subdural space that is created by evacuation of the chronic subdural hematoma (CSDH), and that this, in turn, will reduce the hematoma volume that will then potentially lead to improved functional outcomes, reduced hospitalization time as well as the reduced rate of symptomatic recurrence requiring redo surgery.
The proposed study is a randomized, placebo controlled clinical trial to investigate the effects of D5 ¼NS (treatment) vs. NS (placebo) on residual cSDH volume after surgical drainage via a craniotomy or burr holes.
Participants in the study will be adult patients who had presented with imaging evidence (based on non-contrast head CT) of cSDH requiring surgical evacuation (craniotomy or burr holes). Patients in this study will receive either 5% dextrose ¼Normal Saline (treatment) or Normal Saline (placebo) for 24h after surgery. The study group assignment will be performed based on randomization process prior to the surgery. All the patients will be undergoing a head CT without contrast imaging at 24h after surgery. The residual hematoma volume will be calculated based on XYZ/2 method as previously described (Sucu et al., 2005).
The bedside nursing staff will be provided with either the placebo or D5 ¼NS solutions from the pharmacy in an opaque bag to be administered to the patient after the randomization process has taken place. The procedure for the placebo and treatment solution administration is the same as the standard intravenous fluid administration procedure except the fact of an opaque covering and maintenance of the blinding throughout the process. The bedside nursing staff will administer the intravenous fluid. The infusion rate, as stated, will be 100 cc/h for 24h after SDH evacuation surgery at which time a standard of care head CT without contrast will be obtained. This will be a double-blinded study where blinding will be achieved via the prerandomized enrollment log. Participants signing the consent will be enrolled based on time of enrollment and study ID will be prelinked to a study group of normal saline (placebo) or D51/4NS solution. Pharmacy who will be documenting the treatment allocation and will be issuing the IV fluid for each of the patients will be maintaining the blinding status. The pharmacy staff and coordinator will be the only individuals holding the blinding key which will be released at the official end of the study after all the datapoints have been gathered for all the participants. Additionally, the patients will have basic metabolic panel (BMP as standard of care ) labs drawn every 12 hours during the 24 hour treatment period to assess the electrolyte status and any adverse reactions. The PI and all other study team members, other than the randomizing coordinator, will remain blinded. The unblinded coordinator will not perform any clinical assessments and will not share blinding information with any other team members.
Symptomatic recurrence rates requiring redo surgery within a 90-day period (+/- 7 days) after the initial surgery will be identified via the chart review of each individual study participant.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
normal saline
Drug: Saline
saline with dextrose (D5 ¼NS solutions)
Drug: Dextrose solution
D5 ¼NS solutions
Also known as: saline with dextrose (D5 ¼NS solutions)
normal saline
Also known as: normal saline
Comparative residual CSDH volume (in mm3) measured and calculated using head CT
Comparative residual CSDH volume (in mm3) measured and calculated using head CT
Time frame: 24 hours after surgery
ICU and overall hospitalization length of stay
ICU and overall hospitalization length of stay.
Time frame: duration of total hospital stay assessed for up to 6 months
Functional improvement as measured using mRS scale scores upon admission
Functional improvement as measured using mRS scale scores upon admission, scoring from 0-6, low score with no symptoms and 6 indicating death
Time frame: follow up post surgery assessment up to 6 weeks post release
Symptomatic recurrence rates requiring redo surgery within a 90-day period (+/- 7 days) after the initial surgery
Symptomatic recurrence rates requiring redo surgery within a 90-day period (+/- 7 days) after the initial surgery
Time frame: 90 days post surgery
Plan to share: No
No publications or documents are linked to this record.
Started Jan 2024 (actual). Primary completion is estimated for Dec 2027, 47 months after the start.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Glucose
Carilion Clinic